b) detecting the localization of the labeled ligand in the human, wherein the abnormal localization of VEGF distal from the primary tumor indicates the presence of metastasis in the human.

## Please add the following new claims:

- 21. (New) The method of claim 20 wherein the presence of VEGF is determined using an anti-VEGF antibody.
- 22. (New) The method of claim 20 wherein the presence of VEGF is determined using a VEGF receptor fusion protein or VEGF receptor conjugated protein.
- 23. (New) The method of claim 20 wherein the localization of the ligand is detected using a method entailing X-ray, CAT-scan or MRI.
- 24. (New) The method of claim 20 further comprising detecting the co-localization with VEGF of tyrosine kinase receptors involved in angiogenesis.
- 25. (New) The method of claim 23 wherein the tyrosine kinase receptors are chosen from the group consisting of the *KDR/flk-1* receptor, the *flt-1* receptor, and/or the *tek/tie-2* receptor.

## **REMARKS**

Applicant respectfully requests that the foregoing amendment to Claim 20 and therefore adding new claims 21-25, be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims.

Respectfully submitted,

Date April 11, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Beth A. Burrous Attorney for Applicant Registration No. 35,087

## **VERSIONS WITH MARKINGS TO SHOW CHANGES MADE**

- 20. (Amended) A method of diagnosing metastasis <u>at a site distal from a primary tumor</u> in a human comprising:
- a) <u>administering a</u> detectably [labeling a] <u>labeled</u> ligand which specifically recognizes VEGF[;
  - b) administering the labeled ligand] to the human; and
- [c)] b) detecting the localization of the labeled [antibody or fusion protein] ligand in the human, wherein the abnormal localization of VEGF [is indicative of a metastatic disease] distal from the primary tumor indicates the presence of metastasis in the human.